"They need to nail down the biomarkers that lead to complete resonse but in the mean time extending life is certainly good news."
I remember a conference call where they mentioned that they were were on identifying some biomarkers to target those who would best respond to the treatment. I think they had identified at least one but did not state which biomarker. That could certainly help efficacy.
Agree - likely affirming data supporting the pending EMA transaction.
Numbers better than current SOC even with advanced stage disease population. Future applications will involve sorting the target population to isolate patients with receptive biomarkers elevating OS to roughly 50-52%.
See Dr. Petit biomarker presentation at June ‘17 Investor Conference. Noteworthy information that has received minimal coverage.